{"entity":{"id":"paper-predomix-metabolome-cancer-rep-2024","kind":"paper","name":"Development of a Serum Metabolome-Based Test for Early-Stage Detection of Multiple Cancers","aka":[],"tldr":"PredOmix, an Indian company, reported that a blood test reading thousands of small molecules by mass spectrometry told 30 cancers from no cancer with about 98% accuracy in 6,445 people; the paper gives few further details.","summary":"Nagarkar and colleagues (HCG cancer centres with PredOmix Technologies, Gurugram) profiled serum metabolites by untargeted liquid chromatography and high-resolution mass spectrometry and applied the company's machine-learning algorithm in an investigator-initiated trial of 6,445 participants, cancer patients and non-cancer volunteers (CTRI/2023/03/050316). The abstract reports that the platform detected 30 cancers in women and men with an average accuracy of about 98%, and that accuracy did not vary across the four stages. It builds on the company's earlier test for 15 cancers in women (Gupta et al., Scientific Reports 2023).","asOf":"2026-11-03","links":[{"label":"Cancer Reports 2024","url":"https://doi.org/10.1002/cnr2.70042"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/39559978/"},{"label":"Gupta et al., Scientific Reports 2023 (15 cancers in women)","url":"https://doi.org/10.1038/s41598-023-46553-7"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced"],"targets":[],"drugs":["oncoveryx"],"companies":["predomix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-reports"],"dependsOn":[],"notes":[],"journal":"Cancer Reports","year":2024,"doi":"10.1002/cnr2.70042","pmid":"39559978","authors":"Nagarkar R, Gopichand M, Pal SK, Gupta A, et al.","paperType":"observational","findings":["30 cancers; average accuracy about 98% in 6,445 participants.","Accuracy reported as unchanged across stages I to IV."],"whatItMeans":"The abstract gives an average accuracy but no sensitivity at a stated specificity, no numbers of cancers by type or stage and no screening result; accuracy this high in early cancers has not been reproduced by any other multi-cancer test and needs independent confirmation.","caveats":["Case-control design with known cancers.","No sensitivity, specificity or positive predictive value in the abstract.","Five authors are PredOmix employees and a co-founder holds stock; the work is covered by a patent filing."],"changedPractice":false,"participants":6445},"route":"/key-papers/paper-predomix-metabolome-cancer-rep-2024/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"oncoveryx","kind":"drug","name":"OncoVeryx (PredOmix)","route":"/drugs/oncoveryx/"}],"company":[{"id":"predomix","kind":"company","name":"PredOmix","route":"/companies/predomix/"}],"journal":[{"id":"cancer-reports","kind":"journal","name":"Cancer reports","route":"/journals/cancer-reports/"}]}}